Investigational drug · Phase 2
Fluzoparib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
98
Any phase or sponsor naming "Fluzoparib"
First trial start
2024
Jan 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Fluzoparib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Fluzoparib" as an intervention, largest first.
University Hospital, CaenAcademic, hospital or other
NCT04774406 · 2,336 participants · Start Feb 24, 2021 · Primary completion May 9, 2021
Drug: olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib · For: Cancer
Sites: Caen, France
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAcademic, hospital or other
NCT05406999 · 900 participants (planned) · Start Feb 1, 2020 · Primary completion Dec 31, 2026
Drug: ADT; Abiraterone Acetate and 6 more · For: Neoadjuvant Therapy; High Risk Prostate Cancer; Locally Advanced Prostate Cancer and 1 more
Sites: Nanjing, China
- Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)Pivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05891093 · 766 participants (planned) · Start Jun 1, 2023 · Primary completion May 31, 2028
Drug: Fluzoparib; Anastrozole and 6 more · For: Breast Cancer
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 15 sites in all
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based ChemotherapyPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04229615 · 690 participants · Start Jun 2, 2020 · Primary completion Jun 30, 2023
Drug: Fluzoparib; Apatinib; Fluzoparib and 1 more · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Sites: Beijing, China
- SNF Platform Study of HR+/ HER2-advanced Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05594095 · 620 participants (planned) · Start Dec 30, 2022 · Primary completion Dec 1, 2025
Drug: PIK3CA inhibitor; AKT inhibitor and 17 more · For: Breast Neoplasm; Breast Cancer; Hormone Receptor Positive Tumor and 2 more
Sites: Shanghai, China
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate CancerPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04691804 · 496 participants · Start Mar 18, 2021 · Primary completion Dec 31, 2026
Drug: Fuzuloparib , Abiraterone acetate and Prednisone; Fuzuloparib Placebo, Abiraterone acetate and Prednisone · For: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sites: Anchorage, Alaska; Tucson, Arizona; Rancho Mirage, California · 147 sites in all
Tongji HospitalAcademic, hospital or other
NCT05206890 · 490 participants (planned) · Start Jan 14, 2022 · Primary completion Dec 31, 2026
Drug: fluzoparib monotherapy or combination therapy · For: Ovarian Cancer
Sites: Wuhan, China
- A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA MutationPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04296370 · 474 participants (planned) · Start Jul 13, 2020 · Primary completion Jun 30, 2022
Drug: Fluzoparib; Apatinib; Fluzoparib and 1 more · For: Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Sites: Shanghai, China
- Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian CancerPivotal-lookingRecruiting
Tongji HospitalAcademic, hospital or other
NCT06954584 · 424 participants (planned) · Start May 27, 2025 · Primary completion May 1, 2030
Drug: Bevacizumab; Fluzoparib Monotherapy · For: Ovarian Cancer
Sites: Wuhan, China · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Fluzoparib combined with docetaxel followed by epirubicin and cyclophosphamide as neoadjuvant therapy in HRD-positive and/or gBRCA-mutated HR+/HER2- early breast cancer: a single-arm phase II study.
Wang Z, Yang L, Du P, et al. · Breast Cancer Res Treat 2026
- Photocatalytic Transannular Migration to Stereodefined Cyclobutanes and Bicyclo[2.1.1]hexanes as Benzenoid Bioisosteres.
Ren HS, Xing JP, Bai HM, et al. · Angew Chem Int Ed Engl 2026
- Case Report: Image-guided adaptive lattice radiotherapy for a 2,772-cc ulcerative triple-negative breast cancer.
Xiao M, Wang Q, Yu G, et al. · Front Oncol 2026
- Synchronous primary breast invasive carcinoma and breast metastasis from high-grade serous ovarian carcinoma: a case report and literature review.
Miao J, Liu N, Gong F, et al. · Front Oncol 2026
- Discovery of Phthalazine Derivatives as New PARP1 Inhibitors Through 3D-QSAR, Molecular Docking, and MD Studies.
Sedghamiz T, Asgharpour Hasan Kiyadeh S, Moosavi F, et al. · Iran J Pharm Res 2026
- Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition).
Ma F, Xu B · Cancer Innov 2026
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.